Tag: dual US listing Nasdaq NYSE

Argent BioPharma's $15M AusCann Acquisition Accelerates Nasdaq US Listing Strategy

Argent BioPharma’s $15M AusCann Acquisition Accelerates Nasdaq US Listing Strategy

September 3, 2025• Home Top Stories, Homepage, Latest News, News, Top Stories, Top Story, Trending News, USA

Argent BioPharma Limited (ASX: RGT) stands at a defining moment in its corporate evolution. The clinical-stage biopharmaceutical company...

COLITCO LLP accepts no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. COLITCO LLP or an associate may receive a commission for funds raised.

© 2025 Colitco . All rights reserved